GALT — Belapectin NASH Cirrhosis Phase 2b/3 Trial Completion
Sep 30, 2025, 4:00:00 AM UTC
Summary
Galectin Therapeutics is expected to complete its Phase 2b/3 clinical trial of belapectin for the prevention of esophageal varices in patients with NASH cirrhosis by September 30, 2025. The study evaluates the efficacy and safety of belapectin, a galectin-3 inhibitor, in patients with nonalcoholic steatohepatitis (NASH) cirrhosis and portal hypertension. Successful results could support regulatory filings for belapectin in this indication.
Company
GALECTIN THERAPEUTICS INC (GALT)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
galectintherapeutics.comSimilar Events
NAVIGATE Trial Results Update
Galectin Therapeutics plans to share additional results from the NAVIGATE trial, including specialized biomarker analyses, in the second quarter of 2025, emphasizing belapectin's potential in treating MASH cirrhosis.
clinical readoutPhase 3 Clinical Trial Completion for Pegozafermin in MASH Cirrhosis
89bio, Inc. is conducting a Phase 3 clinical trial evaluating pegozafermin in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). The study, enrolling 762 participants, is expected to complete on August 1, 2031. Pegozafermin is a glycopegylated analog of FGF21, under development for liver and metabolic diseases. The trial's outcome may impact future regulatory submissions and commercial prospects for pegozafermin in advanced MASH.
trial completionEASL 2025 Meeting Presentation
Galectin Therapeutics will present late-breaking data from the NAVIGATE study on belapectin at the EASL 2025 meeting in Amsterdam, highlighting its significance in treating MASH cirrhosis.
conference talkPhase 3 Study Completion of MGL-3196 (Resmetirom) in NASH and Fibrosis
Madrigal Pharmaceuticals is expected to complete its Phase 3 clinical trial of MGL-3196 (Resmetirom) for patients with nonalcoholic steatohepatitis (NASH) and fibrosis by January 1, 2028. The study, involving 1,759 participants, aims to evaluate the efficacy and safety of Resmetirom, a thyroid hormone receptor-beta agonist, in improving liver histology in NASH patients with advanced fibrosis. The trial's results could impact the competitive landscape for NASH therapies, an area with significant unmet medical need.
trial completion